BioBusiness

VAR2 Pharmaceuticals has been selected for its development of a drug-conjugated malaria protein that potentially selectively binds to most human tumor types.

The company now offers its CONFIDENCE virus clearance services to support validation of viral clearance processes.

Citing clinical trial data that hydroxychloroquine did not show benefits for COVID-19 patients, FDA removes emergency use authorization for the drug as a treatment for the novel coronavirus.

Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate.

The companies have entered into a manufacturing agreement for the fill finish supply of lenzilumab for the potential treatment of COVID-19.

The acquisition gives Novovax an annual operating capacity of more that one billion doses of COVID-19 vaccine antigen.

Achieving herd immunity will require testing, data, a vaccine, and public support.

Working with incubators can provide cell and gene therapy developers with more opportunities.

This latest round of funding adds 14 new technology projects, workforce development, and Global Health Fund projects to NIIMBL's portfolio.

Participants in two dosing cohorts in Moderna’s mRNA-1273 study reached or exceeded neutralizing antibody titers generally seen in convalescent sera.

Catalent will manufacture a mRNA-based COVID-19 vaccine for clinical trials and potential commercialization.

FDA/FTC collaborate to end false and misleading statements and discuss the future of biosimilars at March 2020 public workshop on a competitive marketplace for biosimilars.

FDA’s EUA provides the first new treatment for COVID-19 patients with severe symptoms.

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

Having remote operations in place is crucial to maintaining good automation practices.

Viral vectors show promise as a delivery mechanism for gene therapy, but which virus types are commercially viable?

But are innovations sufficient to increase adoption? CMOs are demanding better continuous bioprocessing options.

NIH trial shows remdesivir accelerates recovery; Gilead study shows similar efficacy for 5- and 10-day dosing.

Experts to discuss strategies for ensuring supply of quality drug products during a pandemic in April 28 online event.

Successful negotiation of life-sciences collaboration agreements involves careful planning.

The company closed two new funds, ARCH Venture Fund X and ARCH Venture Fund X Overage, for a total of $1.46 billion combined.

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

As politicians focus on drug cost reduction, biopharmaceutical companies in the US are moving to states with lower taxes and relocating some facilities that had been offshore.

As the coronavirus pandemic unfolds, the bio/pharma industry must practice science over hype.

Johnson & Johnson announces clinical trial plans for COVID-19 vaccine candidate, as well as plans to produce 1 billion vaccine doses.